Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

AbstractVitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin, affecting 0.5 –2% of the population worldwide. It can have a significant impact on patients’ quality of life. In recent years, there has been significant progress in our understanding of the pathogenesis of vitiligo. It is believed that vitiligo develops due to a complex combination of genetics, oxidative str ess, inflammation, and environmental triggers. Conventional treatments include camouflage, topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, phototherapy, and surgical procedures, with the treatment regimen dependent on the patient’s preferences and characteristics. Wi th increased understanding of the importance of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the pathogenesis of vitiligo, treatment has expanded to include the first US FDA-approved cream to repigment patients with vitiligo. This review summarizes our un derstanding of the major mechanisms involved in the pathogenesis of vitiligo and its most common available treatments.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research